Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Summary

The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly reduce depressive symptoms and decrease alcohol consumption compared to placebo in patients with depression and alcohol dependence who are on a stable dose of a selective serotonin reuptake inhibitor (SSRI).

Timeline

Start

2007-08

Primary completion

2014-07

Completion

2014-07

Drugs

Indications